As early as 2004, Matar et al. explored the blocking effect of gefitinib and cetuximab on the EGFR pathway using human cancer cell lines (vulvar squamous carcinoma, prostate carcinoma cells and breast carcinoma cells) and A431 (vulvar squamous carcinoma) xenografts in nude mice (49). Here, EGFR is linked to breast carcinoma.